![](/img/cover-not-exists.png)
PCN87 A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
HG Bischoff, D Heigener, C Wiesner, S WalzerVolume:
12
Year:
2009
Language:
english
DOI:
10.1016/s1098-3015(10)74338-2
File:
PDF, 72 KB
english, 2009